(Q35922156)

11 August 2017

1 reference

title

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity (English)

1 reference

11 August 2017

Ingelman-Sundberg M

1

1 reference

11 August 2017

1 January 2005

1 reference

The Pharmacogenomics Journal

11 August 2017

1 reference

11 August 2017

5

1 reference

11 August 2017

6-13

1 reference

11 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500285

11 August 2017

0 references

cites work

Moving towards individualized medicine with pharmacogenomics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Pharmacogenetics and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Pharmacogenetics goes genomic

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Inheritance and drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

A refined substrate model for human cytochrome P450 2D6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Relationship between personality and debrisoquine hydroxylation capacity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Association between cytochrome P450 2D6 genotype and harm avoidance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Influence of the defective metabolism of sparteine on its pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Molecular cloning of a family of xenobiotic-inducible drosophilid cytochrome p450s: evidence for involvement in host-plant allelochemical resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

A single p450 allele associated with insecticide resistance in Drosophila.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Point mutations associated with insecticide resistance in the Drosophila cytochrome P450 Cyp6a2 enable DDT metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Polymorphic hydroxylation of perhexiline in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Summary of information on human CYP enzymes: human P450 metabolism data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500285

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500285

1 reference

11 August 2017

1 reference

PubMed ID

15492763